These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 20379286

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases.
    Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, Otori Y, Kamei M, Kusaka S, Tano Y.
    Ophthalmology; 2008 Sep; 115(9):1571-80, 1580.e1-3. PubMed ID: 18440643
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series.
    Kotecha A, Spratt A, Ogunbowale L, dell'Omo R, Kulkarni A, Bunce C, Franks WA.
    Arch Ophthalmol; 2011 Feb; 129(2):145-50. PubMed ID: 21320957
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-VEGF intravitreal bevacizumab for radiation-associated neovascular glaucoma.
    Nagendran ST, Finger PT.
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):201-7. PubMed ID: 25707045
    [Abstract] [Full Text] [Related]

  • 9. Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients.
    Sugimoto Y, Mochizuki H, Okumichi H, Takumida M, Takamatsu M, Kawamata S, Kiuchi Y.
    Graefes Arch Clin Exp Ophthalmol; 2010 Nov; 248(11):1601-9. PubMed ID: 20524132
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Angiographic changes in iris and iridocorneal angle neovascularization after intravitreal bevacizumab injection.
    Ishibashi S, Tawara A, Sohma R, Kubota T, Toh N.
    Arch Ophthalmol; 2010 Dec; 128(12):1539-45. PubMed ID: 21149776
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Regression of neovascular iris vessels by intravitreal injection of bevacizumab.
    Mason JO, Albert MA, Mays A, Vail R.
    Retina; 2006 Sep; 26(7):839-41. PubMed ID: 16963866
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical factors related to recurrence of anterior segment neovascularization after treatment including intravitreal bevacizumab.
    Saito Y, Higashide T, Takeda H, Murotani E, Ohkubo S, Sugiyama K.
    Am J Ophthalmol; 2010 Jun; 149(6):964-972.e1. PubMed ID: 20381786
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.
    dell'Omo R, Kulkarni A, Franks WA.
    Acta Ophthalmol; 2008 Sep; 86(6):698-700. PubMed ID: 18081905
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.